Mruk-Med I Sp. z o.o.

The centre is advancing diagnostic imaging and therapeutic delivery systems to support cutting‑edge oncology trials. Research aims to improve the precision of treatment monitoring and to evaluate novel device‑based interventions.

• Development of next‑generation imaging biomarkers
• Integration of robotic surgery platforms
• Evaluation of drug‑eluting implant technologies
• Validation of real‑time tumor response assessments

Mruk‑Med I Sp. z o.o. leverages its hospital setting to combine equipment innovation with patient‑centered trials.

Although the primary focus is oncology, the site conducts exploratory studies on cardiovascular health in cancer patients, addressing therapy‑related cardiac effects and improving risk stratification.

• Monitoring of cardiac function during targeted therapy
• Biomarker studies for chemotherapy‑induced cardiotoxicity
• Assessment of vascular imaging techniques

The multidisciplinary team at Mruk‑Med integrates cardiology expertise to safeguard patient safety during intensive treatment regimens.

The majority of trials focus on solid tumors, evaluating new targeted agents, immunotherapies, and combination regimens across a spectrum of cancers such as breast, colorectal, renal and melanoma. The goal is to extend survival and reduce disease progression.

• Targeted therapy for HER2‑low and HER2‑positive breast cancer
• KRAS G12C‑specific inhibitors for metastatic colorectal cancer
• Anti‑angiogenic strategies in renal cell carcinoma
• Novel antibody‑drug conjugates for refractory solid tumors

With 22 active trials, Mruk‑Med’s oncology program is a hub for innovative cancer research in Poland.

A robust portfolio addresses non‑small cell lung cancer and small‑cell lung cancer, testing immunotherapy combinations, kinase inhibitors, and sequencing strategies to improve outcomes for advanced disease.

• PD‑1/PD‑L1 blockade combined with anti‑angiogenic agents
• EGFR‑mutant lung cancer after surgery
• KRAS‑targeted therapies for NSCLC
• Second‑line treatments for relapsed small‑cell lung cancer

The site’s pulmonology unit collaborates closely with oncology investigators to streamline patient enrollment.

Investigations explore metabolic drivers of tumor growth, such as the PI3K‑AKT pathway, to identify predictive biomarkers and therapeutic windows for metabolic inhibitors.

• PI3K‑mutant hormone‑receptor positive breast cancer studies
• Metabolic profiling of treatment‑resistant tumors
• Combination of metabolic blockers with CDK4/6 inhibitors

By linking laboratory insights with clinical trials, Mruk‑Med aims to translate metabolic research into patient benefit.

Trials examine hormonal and cellular signaling pathways, particularly in endocrine‑sensitive cancers, to refine endocrine therapy and overcome resistance mechanisms.

• CDK4/6 inhibitor sequencing with endocrine therapy
• Novel selective estrogen receptor degraders for advanced breast cancer
• Hormone‑driven tumor response monitoring

The research team at Mruk‑Med leverages its endocrinology expertise to support precision medicine approaches.